The mechanisms mediating hematopoietic stem and progenitor cell (HSPC) mobilization by G-CSF are complex. We have previously found that G-CSF-enforced mobilization is controlled by peripheral sympathetic nerves (PSN) via norepinephrine signaling. Here, we show that G-CSF likely alters sympathetic tone directly and that methods to increase adrenergic activity in the bone marrow (BM) microenvironment enhance progenitor mobilization. PSN neurons express the G-CSF receptor and ex vivo stimulation of PSN neurons with G-CSF significantly reduced norepinephrine (NE) re-uptake, suggesting that G-CSF potentiates the sympathetic tone by increasing NE availability. Based on these data, we tested the NE reuptake inhibitor desipramine in HSPC mobilization. While desipramine did not by itself elicit circulating HSPC, it significantly increased G-CSF-triggered mobilization efficiency, and rescued mobilization in a model mimicking "poor mobilizers". Thus, these data suggest that blockade of NE reuptake may be a novel therapeutic target to increase stem cell yield in patients.
Introduction
Hematopoietic stem and progenitor cells (HSPC) continuously traffic between the blood and bone marrow under homeostasis.
1,2 G-CSF can enhance this phenomenon and has emerged as one of the most potent and safe agents to mobilize HSPC for stem cell transplantation, but its mechanisms are complex. Studies have attributed its mobilizing activity to the release of neutrophil-derived proteolytic enzymes that leads to the cleavage of CXCL12 and other retention signals. 3, 4 However, this model has been challenged by the normal mobilization found in absence of serine protease and metalloproteinase activity. 5 Therefore, this suggests functional redundancy with other proteases or involvement of additional mechanisms. Adrenergic signals play a key role in the release of HSPC either when enforced by G-CSF 6 or during steady state. 1 Egress is associated with the downregulation in Nestin + niche cells of Cxcl12 mRNA expression and other genes (Kitl, Angpt1, Vcam1) that contribute to HSPC retention in the bone marrow. 7 However, expression of the G-CSF receptor (encoded by Csf3r) on transplantable hematopoietic cells has been reported to be required for mobilization, 8 and recent studies suggest that this cell may be a macrophage 9-11 whose activity promote HSC retention by the niche. 9 Since the administration of either G-CSF or β3 adrenergic agonists has the same effect on the expression of these retention factors by the niche, 7 it suggests that increased sympathetic tone may enhance mobilization.
Methods
Eight-week-old male C57BL/6J mice were purchased from the National Cancer Institute or saline treatment were started 4 days prior G-CSF treatment and continued throughout the experiment. For AMD3100-induced mobilization mice were treated with Desipramine (10mg/kg i.p.) or saline as described above. On day 8 mice were injected with AMD3100 (5mg/kg s.c.) 1 h before blood was harvested by retroorbital bleeding. All other experimental methods are described in supplemental Methods.
Results and Discussion
We performed immunofluorescence analyses in murine superior cervical sympathetic ganglia (SCSG) to assess the expression of Csf3r in PSN. SCSG neurons have large cell bodies and express the catecholaminergic enzyme tyrosine hydroxylase (TH) ( Figure 1A ).
These SCSG neurons also expressed specifically Csf3r (Fig.1A) , and Csf3r mRNA ( Figure   1B ). This is consistent with other studies that have shown Csf3r expression in neocortical neurons and that G-CSF promotes neuronal survival following ischemic brain injury. 15 The activity of the natural neurotransmitter of the sympathetic nervous system, NE, is tightly regulated by a balance of secretion and reuptake by nerve terminals. 16 To determine whether Csf3r on sympathetic neurons was functional, we evaluated whether G-CSF could influence NE release. In these studies, isolated SCSGs were loaded with tritiated norepinephrine ([3H]-NE), and the ability of G-CSF to increase the release of radiolabelled NE in these organ cultures was assessed. While control KCl induced profound NE release, there was no difference in [3H]-NE content in the media between unstimulated or G-CSFtreated cultures (Supplementary Figure 1) . We then evaluated the influence of G-CSF on the re-uptake of NE by PSN. To this end, SCSG were cultured in media containing [3H]-NE in the presence or absence of G-CSF. We found that incubation with G-CSF significantly reduced [3H]-NE re-uptake when compared to the unstimulated control ( Figure 1C ). Preincubation with an antibody that blocked Csf3r abrogated this effect indicating that the effect was specific ( Figure 1C ). These data thus suggest that G-CSF enhances the sympathetic tone by altering the ability of sympathetic neurons to take up NE, thereby increasing
For personal use only. on May 31, 2017. by guest www.bloodjournal.org From catecholamines available to target cells. The drug desipramine, a NE reuptake inhibitor, completely blocked NE uptake in SCSG organ culture ( Figure 1C ). This led us to investigate whether in vivo blockade of NE reuptake could enhance G-CSF mobilization efficiency.
Mice were treated with desipramine and G-CSF as depicted in Figure 2A .
Desipramine alone did not mobilize HSPC ( Supplementary Figure 2A-B) , an observation consistent with previous studies indicating that β-adrenergic agonists are not sufficient to induce robust mobilization, 6 and that other G-CSF-mediated signals cooperate with adrenergic receptors. 1, 6, 9 When administered in conjunction with G-CSF, desipramine significantly increased the number of clonogenic progenitors (CFU-C) and Lin (Table S1 and Fig. 2E ). Importantly, we detected no difference in BM cellularity, CFU-C or LSKF cells numbers in the BM (Supplemental Figure 2C -E), indicating that the increase in progenitor mobilization does not result from increased numbers in the bone marrow. Consistent with the fact desipramine treatment enhanced G-CSF-induced sympathetic outflow, it did not affect AMD3100-induced mobilization (Fig. S2F-G ). This notion is further supported by results where another selective NE reuptake blocker, reboxetine, enhanced G-CSF-induced mobilization to a similar extent (Fig. S2H-I ).
We reasoned that patients who mobilize poorly might benefit from increased sympathetic tone more than healthy individuals. To test this idea in a pre-clinical setting, we modeled "poor mobilizers"-which commonly result from prior cytotoxic therapy 17 -by subjecting mice to a lethal dose of irradiation and BM transplantation. Following a four-month recovery period, mice were treated with desipramine and mobilized with G-CSF ( Figure 2F ). 
